Compare Biogen Inc (BIIB) vs Dominion Energy Inc (D) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Dominion Energy Inc — how do they compare? Biogen Inc trades at $204.1 (market cap $30.60B), while Dominion Energy Inc trades at $68.36 (market cap $59.06B). The key difference: Dominion Energy Inc is the larger of the two by market cap, and Dominion Energy Inc pays a 3.98% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | D | |
|---|---|---|
Market Cap | $30.60B | $59.06B |
Sector | Health | Utilities |
52-Week High | $216.63 | $71.67 |
52-Week Low | $128.93 | $57.08 |
Enterprise Value | $37.67B | $113.18B |
Dividend Yield | — | 3.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.94, up 0.8% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $234.47. The company has beaten earnings estimates for three consecutive quarters, including Q2 2026 EPS of $3.60 versus $2.94 expected, and recently completed the acquisition of RayThera Inc. to bolster its immunology pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%.
The outlook is positive, driven by strong execution and growth from newer drugs like Leqembi, though risks include pressure on legacy multiple sclerosis sales and a high P/E ratio of 36.93. The stock offers potential upside to the analyst target but faces earnings volatility and integration risks from recent acquisitions.
Dominion Energy (D) trades at $67.39, up 0.88% today, with a bearish technical signal but strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.79, exceeding expectations, and maintains a stable dividend. Revenue growth is robust, rising to $16.51B in 2025, with a net income margin of 13.99%. Analyst consensus is mixed, with a $70.43 price target, but technical indicators show resistance near $68.
Outlook remains cautious due to high debt levels and bearish technicals, though fundamentals are solid with consistent profitability. Risks include regulatory pressures and capital expenditure demands. The stock offers income appeal with dividends, but near-term price action may face headwinds from technical selling pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Dominion Energy Inc
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →
